Biotech
OncoGenex Prostate Drug Extends Survival
A new cancer drug from OncoGenex Pharmaceuticals(OGXI) extended the survival of patients with advanced prostate cancer by almost seven months, according to results from a randomized phase II study presented Saturday at the American Society of Clinical Oncology (ASCO) annual meeting.
OncoGenex and its drug, known as OGX-011, were flying under the radar of many investors until about two weeks ago. That changed when a research abstract showing promising results for OGX-011 was released online in advance of the ASCO meeting. Soon after, Johnson & Johnson(JNJ) announced the $1 billion acquisition of Cougar Biotechnology(CGRB), another small biotech firm with a prostate cancer drug in development. Shares of OncoGenex tripled in the past two weeks to more than $21 a share. The stock closed Friday at $17.65 as investors took profits ahead of this weekend's ASCO meeting. The phase II study presented Saturday enrolled 82 men with advanced prostate cancer who had not yet begun chemotherapy treatment. The patients were randomized to receive either a combination of OGX-011 plus Taxotere or Taxotere alone. Taxotere is the most commonly used treatment for prostate cancer. The median overall survival for the men treated with OGX-011 plus Taxotere was 23.8 months compared to 16.9 months for men treated with Taxotere alone -- an improvement in survival of 6.9 months favoring OGX-011. Expressed another way, treatment with OGX-011 reduced the risk of death by 39% compared to treatment with Taxotere alone. The survival benefit seen in the OGX-011 study was not statistically significant, although the study wasn't designed to definitively prove the drug's ability to prolong survival. The 6.9-month survival advantage was also lower than the 10-month survival benefit first reported in the ASCO research abstract published online on May 14.TheStreet Premium Services
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn MoreOptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn MoreReal Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn MoreStocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn MoreTo begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,454.83 | 1,317.82 | 2,837.53 | 17.45 |
Oil *
107.03
|
|
DOWN
74.92 |
DOWN
2.86 |
DOWN
1.85 |
DOWN
0.14 |
10 Yr
1.74%
SPDR Gold
152.68
|
|
-0.60%
|
-0.22%
|
-0.07%
|
-0.80%
|
Data delayed 20 minutes |


Connect with TheStreet